| Literature DB >> 22614899 |
Jessica M Fogel1, Taha E Taha, Jin Sun, Donald R Hoover, Teresa L Parsons, Johnstone J Kumwenda, Lynne M Mofenson, Mary Glenn Fowler, Craig W Hendrix, Newton I Kumwenda, Susan H Eshleman, Mark Mirochnick.
Abstract
First-line antiretroviral treatment regimens in resource-limited settings used in breastfeeding mothers often include stavudine (d4T). Limited data describing d4T concentrations in breast milk are available. We analyzed d4T concentrations in 52 mother-infant pairs using ultra-performance liquid chromatography-tandem mass spectrometry (lower limit of quantification: 5 ng/mL in plasma, 20 ng/mL in breast milk). Median (interquartile range) d4T concentrations were 86 (36-191) ng/mL in maternal plasma, 151 (48-259) ng/mL in whole milk, 190 (58-296) ng/mL in skim milk, and <5 (<5 to <5) ng/mL in infant plasma. Although d4T is concentrated in breast milk relative to maternal plasma, the infant d4T dose received from breast milk is very small and not clinically significant.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22614899 PMCID: PMC3404155 DOI: 10.1097/QAI.0b013e31825ddcfa
Source DB: PubMed Journal: J Acquir Immune Defic Syndr ISSN: 1525-4135 Impact factor: 3.731